Cargando…

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

BACKGROUND: Myocardial fibrosis is a multistep process, which results in collagen deposition in the injured muscle. Empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), decreases cardiovascular events risk. Little is known on the effects of empagliflozin in non-diabetic patients early...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daud, Elias, Ertracht, Offir, Bandel, Nadav, Moady, Gassan, Shehadeh, Monah, Reuveni, Tali, Atar, Shaul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254247/ https://www.ncbi.nlm.nih.gov/pubmed/34215277 http://dx.doi.org/10.1186/s12933-021-01322-6

Ejemplares similares

The Role of Extracellular Signal-Regulated Kinase Pathways in Different Models of Cardiac Hypertrophy in Rats
por: Moady, Gassan, et al.
Publicado: (2023)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
por: Saad, Ranin, et al.
Publicado: (2022)

Takotsubo Syndrome During the COVID-19 Pandemic: State-of-the-Art Review
por: Moady, Gassan, et al.
Publicado: (2021)

Stress-Induced Cardiomyopathy—Considerations for Diagnosis and Management during the COVID-19 Pandemic
por: Moady, Gassan, et al.
Publicado: (2022)

The impact of on-site cardiac surgical backup on clinical outcomes of acute coronary syndrome—analysis of the ACSIS national registry
por: Moady, Gassan, et al.
Publicado: (2023)

The Prognostic Value of Natriuretic Peptides in Stable Patients with Suspected Acute Myocarditis: A Retrospective Study
por: Moady, Gassan, et al.
Publicado: (2022)

Cardiac assessment accuracy by students using palm-held ultrasound compared to physical examination by skilled cardiologists: a pilot study with a single medical student
por: Sarig, Shirley, et al.
Publicado: (2022)

Management of Patients with Left Ventricular Assist Device during the COVID-19 Pandemic
por: Moady, Gassan, et al.
Publicado: (2022)

Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
por: Moady, Gassan, et al.
Publicado: (2023)

The Role of Stress in Stable Patients with Takotsubo Syndrome—Does the Trigger Matter?
por: Moady, Gassan, et al.
Publicado: (2022)

Ventricular Assist Devices: Challenges of the One-device Era
por: Moady, Gassan, et al.
Publicado: (2022)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

The Use of Empagliflozin Post Myocardial Infarction
por: Ravendran, Kapilraj, et al.
Publicado: (2023)

Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
por: Gaborit, B., et al.
Publicado: (2021)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
por: Lee, Hsiang-Chun, et al.
Publicado: (2019)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
por: Mozawa, Kosuke, et al.
Publicado: (2021)

Exploratory echocardiographic strain parameters for the estimation of myocardial infarct size in ST‐elevation myocardial infarction
por: Dannenberg, Varius, et al.
Publicado: (2021)

The cardioprotective efficacy of TVP1022 against ischemia/reperfusion injury and cardiac remodeling in rats
por: Malka, Assaf, et al.
Publicado: (2016)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
por: Hu, Zhaoyang, et al.
Publicado: (2021)

Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA
por: Paolisso, Pasquale, et al.
Publicado: (2021)

Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
por: Wilton, Stephen B., et al.
Publicado: (2021)

Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non‐ST Elevation Myocardial Infarction registries
por: Puymirat, Etienne, et al.
Publicado: (2018)

Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies
por: Wang, Haipeng, et al.
Publicado: (2022)

Accumulation of cis- and trans-regulatory variations is associated with phenotypic divergence of a complex trait between yeast species
por: Lupo, Offir, et al.
Publicado: (2021)

The Association of Suicidal Ideation With Firearm Purchasing During a Firearm Purchasing Surge
por: Anestis, Michael D., et al.
Publicado: (2021)

Trends in conventional cardiovascular risk factors and myocardial infarction subtypes among young Chinese men with a first acute myocardial infarction
por: Zhang, Min, et al.
Publicado: (2021)

Appropriateness of gastrointestinal prophylaxis use during hospitalization in patients with acute myocardial infarction: Analysis from the China Acute Myocardial Infarction Registry
por: Shi, Wence, et al.
Publicado: (2020)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics
por: Cinquegrani, Gloria, et al.
Publicado: (2022)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Association of Myocardial Injury With Serum Procalcitonin Levels in Patients With ST-Elevation Myocardial Infarction
por: Reindl, Martin, et al.
Publicado: (2020)

Anemia and Inflammation in ST-Segment Elevation Myocardial Infarction
por: Zhang, Enyuan, et al.
Publicado: (2015)

Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction
por: Cui, Yuxia, et al.
Publicado: (2019)

Management and outcome across the spectrum of high‐risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk‐score for secondary prevention
por: Grinberg, Tzlil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_umj8gnresvmg8ruvk3ea508aue